Enveric Biosciences (NASDAQ:ENVB) spotted trading -81.32% off 52-week high price. On the other end, the stock has been noted 58.05% away from the low price over the last 52-weeks. The stock changed -5.04% to recent value of $3.96. The stock transacted 1036565 shares during most recent day however it has an average volume of 646.00K shares. The company has 5.29M of outstanding shares and 2.16M shares were floated in the market.
On Jan. 15, 2021, Enveric Biosciences (NASDAQ:ENVB) a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, released the closing on January 14, 2021, of its $10 million registered direct offering consisting of the purchase and sale of 2,221,358 shares of Enveric’s common stock and common stock equivalents, at a purchase price of $4.5018 per share. Also, Enveric has issued to the investors unregistered warrants to acquire 1,666,019 shares of Common Stock at $4.9519 per share, exercisable immediately and terminating five years after the date of issuance.
The net proceeds to Enveric from the offering after deducting financial advisory fees and other costs and expenses were approximately $9 million. Enveric intends to use the net proceeds from this offering for working capital and general corporate purposes.
Its earnings per share (EPS) expected to touch remained 86.20% for this year. ENVB has a gross margin of 20.70% and an operating margin of -16.40% while its profit margin remained -20.60% for the last 12 months.
According to the most recent quarter its current ratio was 0.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of -33.11% from the mean of 20 days, -31.90% from mean of 50 days SMA and performed -30.51% from mean of 200 days price. Company’s performance for the week was -12.78%, -40.72% for month and YTD performance remained -7.04%.